The present disclosure provides methods of improving the resolution of labeled glycans in capillary electrophoresis techniques using a gel as a sieving matrix, by incorporating polyamines in the gel.

The present invention relates to a biocompatible nanoparticle and a use thereof and, more specifically, to a biocompatible nanoparticle formed by irradiation an electron beam to an aqueous solution comprising at least one substance selected from the group consisting of a polysaccharide, a derivative thereof and a polyethylene glycol, thereby inducing inter-molecular cross-linking or intra-molecular cross-linking, and to a use of the biocompatible nanoparticle in a drug carrier, a contrast agent, a diagnostic agent or an intestinal adhesion prevention agent or for disease prevention and treatment.

Disclosed is a fluorescently labeled polysaccharide. The fluorescently labeled polysaccharide is formed by covalently coupling a polysaccharide to a fluorescent dye having a structure as shown in Formula I. A stable covalent bond is form between the polysaccharide molecule and the fluorescent dye molecule. The fluorescently labeled polysaccharide has high stability in serum and other detection environments, has high biocompatibility, and is applicable to the detection of carbohydrate molecules inside and outside cells. Due to a large Stokes shift of the fluorescent dye molecule, the fluorescently labeled polysaccharide has advantages of high fluorescence stability, high fluorescence quantum yields, and achieves high signal-to-noise ratios in imaging results. Further disclosed is a method for preparing the fluorescently labeled polysaccharide. The method has mild reaction conditions and high reaction selectivity, is simple to execute, and can be used to prepare a fluorescently labeled polysaccharide in high yield.

Described herein are efficient, low cost methods for making prebiotics that contain maltosyl-isomaltooligosaccharides (MIMOs), as well as compositions made by such methods.

The present invention relates to storage-stable formulations of oligosaccharide preparations suitable for use in nutritional compositions such as animal feed.

This disclosure relates to synthetic oligosaccharide subunits of the Pseudomonas exosaccharide Psi and uses thereof, e.g., for epitope mapping of anti-Psl antibodies, for identification of anti-Psl antibodies, and for use as vaccines. In one aspect a synthetic oligosaccharide subunit of a Pseudomonas aeruginosa Psl oligosaccharide is provided, comprising the trisaccharide of formula I.

The present invention relates to compositions comprising fractionated alkylated cyclodextrin compositions having a single degree of substitution, and processes for preparing and using the same.

An organic material production system includes: a pretreatment device (12) that pulverizes a biomass material (11); a hydrothermal decomposition apparatus (14) that hydrothermally decomposes a pulverized biomass (13) by causing it to countercurrently contact with hot compressed water (15), elutes lignin components and hemicellulose components into the hot compressed water (15), and separates the lignin components and the hemicellulose components from a biomass solid residue; a first enzymatic hydrolysis device (19-1) that treats cellulose in a biomass solid residue (17), discharged from the hydrothermal decomposition apparatus, with an enzyme (18) to enzymatically hydrolyze it to a sugar solution containing hexose; a fermenter (21) that produces ethanol by fermentation using a sugar solution (20) obtained by the first enzymatic hydrolysis device (19-1); and a refiner 25 that refines an alcohol fermentation liquid (22), so as to separate it into ethanol (23) and a residue (24).

The disclosure generally relates to poly alpha-1,3-glucan compositions and articles containing them. In particular interest is comprising poly alpha-1,3-glucan ester derivatives. The poly alpha-1,3-glucan derivatives are useful in thermoprocesses and in particular, injection molding processes.

In alternative embodiments, the invention provides vaccines, pharmaceutical compounds and formulations for diagnosing, preventing, treating or ameliorating Group A Streptococcus (GAS), Group C Streptococcus (GCS), or Group A Streptococcus (GGS), infections, or other pathogenic Streptococcus infections. In alternative embodiments, the invention provides compositions such as diagnostic tests, assays, immunoassays and test strips, and methods, for detecting or diagnosing the presence of a Streptococcal infection, e.g., Group A Streptococcus (GAS), Group C Streptococcus (GCS), or Group A Streptococcus (GGS), infections, or other pathogenic Streptococcus infections.